Reslizumab (Cinqair®)

Cinqair (reslizumab) is covered as add‑on maintenance therapy at 3 mg/kg IV every 4 weeks for adults ≥18 with severe eosinophilic asthma who have a documented blood eosinophil count ≥400 cells/µL and at least 3 consecutive months of specified controller therapy (patients <18 or those not meeting eosinophil/prior‑therapy criteria are excluded). Initial approval (6 months) requires specialist involvement and documentation of uncontrolled asthma (exacerbations, FEV1 <80% or FEV1/FVC <0.80, or OCS‑dependent), and reauthorization (12 months) requires ≥6 months of prior Cinqair, continued ICS therapy, and documented clinical benefit.

"Initial approval limited to 6 months; renewal approval duration is 12 months."

Sign up to see full coverage criteria, indications, and limitations.